Controlled study by multiple testing units, which is optional and open

Participating institutions:

Department of Neurology. PLA General Hospital
Department of Neurology. Affiliated Second Hospital of Zhejiang University
Department of Neurology. Affiliated Third Hospital of Zhongshan University
Standards for selecting cases:
Neuralgia patients
18 years ≤ age ≤ 80 years
Medicines studied:
Medicine tested: Analgecine
Positive control: Neurotropin
Number of cases
Analgecine 67. positive control 68
Administration
3 ml each time, 2 times each day.
intramuscular injection, two consecutive weeks
Disease statistics of two groups of patients
Names of diseases
Analgecine group (number of cases)
Control group (number of cases)
Total77 patient*time (67 patients)74 patient*time (68 patients)
nervo root type cervical spondylosis1312
sciatica2933
trigeminal neuralgia87
occipital neuralgia67
postherpetic neuralgia31
intercostal neuralgia21
multiple peripheral neuralgia52
diabetes peripheral neuralgia33
thalamencephalon31
neuralgia caused by peripheral nerve damage57

Result 1: Treating neuralgia

treating-neuralgia

Result 2: Treating hypoesthesia, hyperaesthesia, numbness, cold feel, fatigue

treating-hypoesthesia

Conclusion:

Analgecine had a total 93.93% of response rate (cure rate plus remarkable effective rate plus effective rate) of treating neuralgia for two weeks, and 53.03% of effective rate for various concomitant symptoms. Analgecine has the advantages of remarkable and fast curative effect, good adaptability, less side effects, high safety, and is highly recommended for popular clinical application.